Gastroesophageal reflux disease - The long and the short of therapeutic options

被引:10
作者
Brady, WM
Ogorek, CP
机构
[1] TEMPLE UNIV, SCH MED, GASTROENTEROL SECT, PHILADELPHIA, PA 19122 USA
[2] TEMPLE UNIV, SCH MED, GEN INTERNAL MED SECT, PHILADELPHIA, PA 19122 USA
关键词
D O I
10.3810/pgm.1996.11.110
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Gastroesophageal reflux disease (GERD) is a common and treatable condition. Initial therapy includes lifestyle modifications, avoidance of certain medications, and use of antacids, alginic acid preparations, and over-the-counter histamine, (H-2) receptor antagonists. Escalation of therapy for acute disease relies primarily on H-2 receptor antagonists given in conventional dosages, Although H-2 receptor antagonists remain the cornerstone of therapy, sucralfate and promotility agents, especially cisapride, may offer alternatives. Most cases of GERD that are resistant to these therapies can be reliably healed with proton pump inhibitors (PPLs). Patients whose GERD is healed with one of the aforementioned agents often relapse unless they receive further therapy. For patients with mild disease, H-2 receptor antagonists, cisapride, or a combination of the two may prevent recurrent symptoms. In severe disease, PPIs are the agents of first choice, but concerns about the safety of long-term use must be considered, In selected patients, surgery offers an option for long-term control of GERD. With present surgical techniques, symptom relief can be obtained with little risk of complications.
引用
收藏
页码:76 / +
页数:1
相关论文
共 21 条
[1]   ALGINIC ACID DECREASES POSTPRANDIAL UPRIGHT GASTROESOPHAGEAL REFLUX - COMPARISON WITH EQUAL-STRENGTH ANTACID [J].
CASTELL, DO ;
DALTON, CB ;
BECKER, D ;
SINCLAIR, J ;
CASTELL, JA .
DIGESTIVE DISEASES AND SCIENCES, 1992, 37 (04) :589-593
[2]  
CASTELL DO, 1991, ALIMENT PHARM THERAP, V5, P59
[3]   SURGERY FOR UNCOMPLICATED GASTROESOPHAGEAL REFLUX [J].
DEHN, TCB .
GUT, 1992, 33 (03) :293-294
[4]   The diagnosis and treatment of gastroesophageal reflux disease in a managed care environment - Suggested disease management guidelines [J].
Fennerty, MB ;
Castell, D ;
Fendrick, AM ;
Halpern, M ;
Johnson, D ;
Kahrilas, PJ ;
Lieberman, D ;
Richter, JE ;
Sampliner, RE .
ARCHIVES OF INTERNAL MEDICINE, 1996, 156 (05) :477-484
[5]  
*GALL ORG, 1988, HEATB AM GALL ORG SU
[6]   DOUBLE-BLIND COMPARISON OF CISAPRIDE AND CIMETIDINE IN TREATMENT OF REFLUX ESOPHAGITIS [J].
GALMICHE, JP ;
FRAITAG, B ;
FILOCHE, B ;
EVREUX, M ;
VITAUX, J ;
ZEITOUN, P ;
FOURNET, J ;
SOULE, JC .
DIGESTIVE DISEASES AND SCIENCES, 1990, 35 (05) :649-655
[7]   CURRENT TRENDS IN THE PHARMACOTHERAPY FOR GASTROESOPHAGEAL REFLUX DISEASE [J].
HIXSON, LJ ;
KELLEY, CL ;
JONES, WN ;
TUOHY, CD .
ARCHIVES OF INTERNAL MEDICINE, 1992, 152 (04) :717-723
[8]   EFFECTS OF RANITIDINE AND CISAPRIDE ON ACID REFLUX AND ESOPHAGEAL MOTILITY IN PATIENTS WITH REFLUX ESOPHAGITIS - A 24-HOUR AMBULATORY COMBINED PH AND MANOMETRY STUDY [J].
INAUEN, W ;
EMDE, C ;
WEBER, B ;
ARMSTRONG, D ;
BETTSCHEN, HU ;
HUBER, T ;
SCHEURER, U ;
BLUM, AL ;
HALTER, F ;
MERKI, HS .
GUT, 1993, 34 (08) :1025-1031
[9]   MEDICAL THERAPY FOR GASTROESOPHAGEAL REFLUX DISEASE [J].
JOHNSON, DA .
AMERICAN JOURNAL OF MEDICINE, 1992, 92 :S88-S97
[10]   Atrophic gastritis and Helicobacter pylori infection in patients with reflux esophagitis treated with omeprazole or fundoplication [J].
Kuipers, EJ ;
Lundell, L ;
KlinkenbergKnol, EC ;
Havu, N ;
Festen, HPM ;
Liedman, B ;
Lamers, CBHW ;
Jansen, JBMJ ;
Dalenback, J ;
Snel, P ;
Nelis, GF ;
Meuwissen, SGM .
NEW ENGLAND JOURNAL OF MEDICINE, 1996, 334 (16) :1018-1022